Dr. Jeremy Michael Robbins, MD

Dr. Robbins practices at Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health.

Dr. Robbins' NPI, 1003101148, was assigned on June 16, 2011. Dr. Robbins graduated from University of Massachusetts Medical School in 2011. Dr. Robbins holds Massachusetts license 257541.

Dr. Robbins' primary practice is Beth Israel Deaconess Medical Center, at 330 Brookline Avenue, Boston, MA 02215 in Suffolk County. The practice phone is (617) 667-7000.

Dr. Robbins' primary practice is Beth Israel Deaconess Medical Center in Boston, Massachusetts, part of Beth Israel Lahey Health. Dr. Robbins is also affiliated with Beth Israel Deaconess Hospital-Needham. The medical group on file is Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center (HMFP). Dmand AI also links Dr. Robbins to 3 more hospitals, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Robbins practices, 7 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Robbins' primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dr. Robbins is licensed in Massachusetts.

CMS data shows 704 Medicare services from Dr. Robbins across 8 procedure codes in 2024, for 442 Medicare patients. Medicare paid $39,738 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 442 Medicare patients who saw Dr. Robbins in 2024. The largest group is 75 to 84, with 177 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 22% are also on Medicaid. Their average risk score is 1.87, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Robbins' median patient age at 70, with 39% women.

In 2024, Dr. Robbins wrote 651 Medicare Part D claims for 107 patients. 72% of them were for generic drugs. CMS names the drug for 562 of them, across 18 drugs with 11 or more claims each, at $198,855 in total drug cost. In 2023, CMS named 560 claims across 16 drugs.

Dr. Robbins accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Robbins as offering telehealth.

Dmand AI links 39 papers to Dr. Robbins, published from 2015 to 2024. 2021 was the busiest year, with 7. The most frequent topics are Exercise, Cardiovascular Diseases and Proteomics. Dr. Robbins has published most often in JAMA Cardiol. Dr. Robbins' most frequent co-authors are Usman Ahmad Tahir, MD, Mark D. Benson, MD and Daniel Hunter Katz, MD.

CMS Open Payments shows 99 general payments to Dr. Robbins from 4 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 100% of the total. Edwards Lifesciences Corporation paid the most, $44,215.

Dr. Robbins graduated from University of Massachusetts Medical School in 2011.